Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 Return-on-Tangible-Asset is 14.95% as of Jun. 2026, which is 46% above its 10-year median of 10.27. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 681 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 85.61% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Apotea AB (publ)'s annualizedNet Income for the quarter that ended in Jun. 2026 was kr326 Mil. Apotea AB (publ)'s average total tangible assets for the quarter that ended in Jun. 2026 was kr2,178 Mil. Therefore, Apotea AB (publ)'s annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 14.95%.
The historical rank and industry rank for Apotea AB (publ)'s Return-on-Tangible-Asset or its related term are showing as below:
CHIX:APOTEs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.8 Med: 10.27 Max: 15.04
Current: 11.76
During the past 5 years, Apotea AB (publ)'s highest Return-on-Tangible-Asset was 15.04%. The lowest was 1.80%. And the median was 10.27%.
CHIX:APOTEs's Return-on-Tangible-Asset is ranked better than 85.61% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.5
vs CHIX:APOTEs: 11.76
Apotea AB (publ) (CHIX:APOTEs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Apotea AB (publ) Return-on-Tangible-Asset Related Terms
Apotea AB (publ) Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) Return-on-Tangible-Asset Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.95% mean?
Apotea AB (publ) (CHIX:APOTES) has a Return-on-Tangible-Asset of 14.95% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Apotea AB (publ) and its competitors. This is 46% above median its historical median of 10.27. Over the past decade, Apotea AB (publ)'s Return-on-Tangible-Asset has ranged from 1.80 to 15.04. According to the industry distribution chart, Apotea AB (publ) ranks #98 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 14.4%.
Is Apotea AB (publ)'s Return-on-Tangible-Asset too high?
Apotea AB (publ)'s current Return-on-Tangible-Asset of 14.95% is 46% above median its 10-year median of 10.27. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 15.04. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.50. Apotea AB (publ)'s value of 14.95% is 498% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #98 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Return-on-Tangible-Asset compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #98 out of 681 companies for Return-on-Tangible-Asset. This places Apotea AB (publ) in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.50. Apotea AB (publ)'s value of 14.95% is 498% above this benchmark. Historically, Apotea AB (publ)'s own Return-on-Tangible-Asset has ranged from 1.80 to 15.04 over the past decade. While the company's 10-year median is 10.27 vs. the industry median of 2.50, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.50, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current Return-on-Tangible-Asset of 14.95% is 498% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current Return-on-Tangible-Asset is 14.95%, which is 46% above median its own 10-year median of 10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Return-on-Tangible-Asset of 14.95%. The current Return-on-Tangible-Asset is 14.95%, which is 46% above median its 10-year median of 10.27 and 498% above the Healthcare Providers & Services industry median of 2.50. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Return-on-Tangible-Asset is 14.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
